Present and Future of Immunotherapy for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Triple-negative breast cancer (TNBC) lacks estrogen receptors (ERs), HER2, and progesterone receptors (PRs), presenting a poor prognosis.
• TNBC exhibits higher PD-L1 expression and tumor-infiltrating lymphocytes, suggesting potential for immunotherapy.
• Current immunotherapy, like pembrolizumab with chemotherapy, has improved outcomes but not for all patients.

Purpose of the Study:

• To review the current landscape of immunotherapy in TNBC.
• To explore combination strategies to enhance immunotherapy response rates.
• To discuss emerging immunotherapeutic opportunities for TNBC.

Main Methods:

• Literature review of TNBC and immunotherapy.
• Analysis of current and investigational immunotherapy strategies.
• Evaluation of combination therapies (chemotherapy, targeted therapy, radiotherapy).

Main Results:

• Immunotherapy, particularly pembrolizumab, has shown efficacy in advanced TNBC.
• Combination strategies are crucial for improving response rates in a broader patient population.
• Several novel immunotherapeutic agents are under investigation.

Conclusions:

• Immunotherapy represents a significant advancement in TNBC treatment.
• Combination strategies are essential to overcome current limitations and improve patient outcomes.
• Future research holds promise for new therapeutic approvals in TNBC.